445 related articles for article (PubMed ID: 30848378)
1. Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma.
Considine B; Hurwitz ME
Curr Oncol Rep; 2019 Mar; 21(4):34. PubMed ID: 30848378
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
Atkins MB; Clark JI; Quinn DI
Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
[TBL] [Abstract][Full Text] [Related]
3. Treatment of renal cell carcinoma: Current status and future directions.
Barata PC; Rini BI
CA Cancer J Clin; 2017 Nov; 67(6):507-524. PubMed ID: 28961310
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
[TBL] [Abstract][Full Text] [Related]
5. Advanced renal cell carcinoma: current and emerging management strategies.
Escudier B
Drugs; 2007; 67(9):1257-64. PubMed ID: 17547470
[TBL] [Abstract][Full Text] [Related]
6. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.
Lenis AT; Donin NM; Johnson DC; Faiena I; Salmasi A; Drakaki A; Belldegrun A; Pantuck A; Chamie K
J Urol; 2018 Jan; 199(1):43-52. PubMed ID: 28479237
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma.
Flippot R; Escudier B; Albiges L
Drugs; 2018 Sep; 78(14):1443-1457. PubMed ID: 30187355
[TBL] [Abstract][Full Text] [Related]
9. The Past, Present and Future of Immunotherapy for Metastatic Renal Cell Carcinoma.
Chang AJ; Zhao L; Zhu Z; Boulanger K; Xiao H; Wakefield MR; Bai Q; Fang Y
Anticancer Res; 2019 Jun; 39(6):2683-2687. PubMed ID: 31177102
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy and targeted therapy combinations in renal cancer.
McDermott DF
Curr Clin Pharmacol; 2011 Aug; 6(3):207-13. PubMed ID: 21827391
[TBL] [Abstract][Full Text] [Related]
11. First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy.
Tannir N; Hammers H; Amin A
Curr Med Res Opin; 2018 May; 34(5):825-831. PubMed ID: 29297707
[TBL] [Abstract][Full Text] [Related]
12. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.
Lalani AA; McGregor BA; Albiges L; Choueiri TK; Motzer R; Powles T; Wood C; Bex A
Eur Urol; 2019 Jan; 75(1):100-110. PubMed ID: 30327274
[TBL] [Abstract][Full Text] [Related]
13. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
[TBL] [Abstract][Full Text] [Related]
14. Check point inhibitors a new era in renal cell carcinoma treatment.
Alsharedi M; Katz H
Med Oncol; 2018 May; 35(6):85. PubMed ID: 29728867
[TBL] [Abstract][Full Text] [Related]
15. Recent developments in renal cell cancer immunotherapy.
Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
Expert Opin Biol Ther; 2007 May; 7(5):727-37. PubMed ID: 17477809
[TBL] [Abstract][Full Text] [Related]
16. [Immunotherapy for renal cell carcinoma - current status].
Grimm MO; Foller S
Aktuelle Urol; 2018 Apr; 49(2):187-191. PubMed ID: 29587324
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma.
Hirsch L; Flippot R; Escudier B; Albiges L
Drugs; 2020 Aug; 80(12):1169-1181. PubMed ID: 32601914
[TBL] [Abstract][Full Text] [Related]
18. Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma.
Braun DA; Bakouny Z; Hirsch L; Flippot R; Van Allen EM; Wu CJ; Choueiri TK
Nat Rev Clin Oncol; 2021 Apr; 18(4):199-214. PubMed ID: 33437048
[TBL] [Abstract][Full Text] [Related]
19. Treatment options for metastatic renal cell carcinoma: a review.
Athar U; Gentile TC
Can J Urol; 2008 Apr; 15(2):3954-66. PubMed ID: 18405442
[TBL] [Abstract][Full Text] [Related]
20. The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma.
Ornstein MC; Rini BI
Expert Rev Anticancer Ther; 2016 Jun; 16(6):577-84. PubMed ID: 27144724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]